To begin well for the use combination combination tamoxifen.
Dr. Shortly tamoxifen . Continued, ‘Multiple myeloma is often treated with a combination of therapies with different mechanisms of action , we feel it is important to also consider IMGN901 IMGN901 as part of a multi-agent regimen The profile suggests that it particularly. To begin well for the use combination combination, as it works through a novel mechanism and not with side effects that would limit their ability to be used with other agents have been linked. We expect patient dosing in our study 005 combination study in shortly. ‘.
IMGN901 is an investigational agent designed to kill cancer cells that express CD56, a protein. It consists of a CD56-binding antibody with a potent cancer cell killing agent, attached thereto using an engineered linker. IMGN901 is in Phase I trials for the treatment of CD56-expressing solid tumors and multiple myeloma. It is a wholly owned subsidiary of ImmunoGen. (more…)